Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Eric Prystowsky

Clinical Cardiac Electrophysiology Indianapolis, IN Medical Doctor

NPI 1306815964 CMS profile 13642

8333 Naab Rd Ste 420, Ste 400, Indianapolis, IN 46260

Open in the dashboard

General payments

$1,139,808

428 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Eric Prystowsky of Indianapolis, IN is reported in the CMS Open Payments database as having received $1,139,808 across 428 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $86,976 77
2024 General $81,908 35
2023 General $119,272 86
2022 General $152,435 70
2021 General $124,192 30
2020 General $247,496 32
2019 General $327,529 98

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Eric Prystowsky
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Eric Prystowsky were reported at $86,976. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Eric Prystowsky Clinical Cardiac Electrophysiology median Middle half National median
2019 $327,529 $2,361 $585–$8,260 $163
2020 $247,496 $993 $247–$4,351 $114
2021 $124,192 $1,185 $326–$4,739 $132
2022 $152,435 $2,073 $554–$6,789 $149
2023 $119,272 $2,568 $759–$8,159 $160
2024 $81,908 $2,557 $703–$7,403 $164
2025 $86,976 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $515,160 271 payments
  2. Medtronic Vascular, Inc. $313,009 124 payments
  3. Philips Electronics North America Corporation $137,446 9 payments
  4. Braemar Manufacturing, LLC $130,012 2 payments
  5. Boston Scientific Corporation $19,763 5 payments
  6. Biotronik Inc. $13,226 12 payments
  7. Topera, Inc. $11,015 3 payments
  8. Abbott Laboratories $148 1 payment
  9. BioSig Technologies, Inc. $30 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $759,175 50 payments
  2. Consulting Fee $286,899 11 payments
  3. Travel and Lodging $63,311 137 payments
  4. Food and Beverage $15,659 226 payments
  5. Acquisitions $9,041 1 payment
  6. Compensation for serving as faculty or as a speaker for a medical education program $3,750 1 payment
  7. Current or prospective ownership or investment interest $1,974 2 payments
Products named General payments · program years 2019–2025
  1. Cardiac Monitoring Suite $130,012 2 payments
  2. (7999) SRC Undivided $130,000 1 payment
  3. Farapulse $19,763 5 payments
  4. BioMonitor $9,116 2 payments
  5. Edora 8 DR-T $9,092 1 payment
  6. Acticor 7 VR-T DX $9,092 1 payment
  7. Solia $9,092 1 payment
  8. Rivacor 7 DR-T $9,092 1 payment
  9. (2858) General Consulting $4,661 3 payments
  10. MCOT $2,475 1 payment
  11. Other $6,912 64 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

2,148

Median for Cardiology: 2,533

Drug cost

$959,073

Median for Cardiology: $485,213

Branded share of claims

44%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 598 $721,845
Xarelto Rivaroxaban Brand 104 $136,467
Multaq Dronedarone Hcl Brand 32 $36,438
Entresto Sacubitril/Valsartan Brand 21 $21,220
Dofetilide Generic 97 $16,261
Metoprolol Succinate Generic 394 $6,660
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 122 $4,475
Flecainide Acetate Generic 90 $3,770
Amiodarone Hcl Generic 127 $3,446
Mexiletine Hcl Generic 21 $1,868

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 32 billing codes

Paid by Medicare

$89,020

Medicare's payments for the services billed

Medicare patients

370

Average age 78

Services billed

2,466

149 women, 221 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 74%
Arthritis 45%
Ischemic heart disease 40%
Heart failure 38%
Diabetes 31%
Chronic kidney disease 28%
COPD 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

428 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record